156 related articles for article (PubMed ID: 32131714)
21. Btk Inhibitors as First Oral Atherothrombosis-Selective Antiplatelet Drugs?
Busygina K; Denzinger V; Bernlochner I; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Aug; 119(8):1212-1221. PubMed ID: 31087308
[TBL] [Abstract][Full Text] [Related]
22. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
[TBL] [Abstract][Full Text] [Related]
23. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
[TBL] [Abstract][Full Text] [Related]
24. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
25. Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Wei L; Su YK; Lin CM; Chao TY; Huang SP; Huynh TT; Jan HJ; Whang-Peng J; Chiou JF; Wu AT; Hsiao M
Oncotarget; 2016 Oct; 7(43):69961-69975. PubMed ID: 27564106
[TBL] [Abstract][Full Text] [Related]
26. Severe platelet dysfunction in NHL patients receiving ibrutinib is absent in patients receiving acalabrutinib.
Bye AP; Unsworth AJ; Desborough MJ; Hildyard CAT; Appleby N; Bruce D; Kriek N; Nock SH; Sage T; Hughes CE; Gibbins JM
Blood Adv; 2017 Dec; 1(26):2610-2623. PubMed ID: 29296914
[TBL] [Abstract][Full Text] [Related]
27. ADP-induced platelet aggregation and thrombin generation are increased in Essential Thrombocythemia and Polycythemia Vera.
Panova-Noeva M; Marchetti M; Russo L; Tartari CJ; Leuzzi A; Finazzi G; Rambaldi A; ten Cate H; Falanga A
Thromb Res; 2013 Jul; 132(1):88-93. PubMed ID: 23735588
[TBL] [Abstract][Full Text] [Related]
28. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
29. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man.
May JA; Heptinstall S; Cole AT; Hawkey CJ
Thromb Res; 1997 Oct; 88(2):183-92. PubMed ID: 9361371
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous Platelet Aggregation in Blood Is Mediated by FcγRIIA Stimulation of Bruton's Tyrosine Kinase.
Duan R; Goldmann L; Li Y; Weber C; Siess W; von Hundelshausen P
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008508
[TBL] [Abstract][Full Text] [Related]
31. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
32. The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.
Bhatt V; Alejandro L; Michael A; Ganetsky A
Pharmacotherapy; 2014 Mar; 34(3):303-14. PubMed ID: 24338680
[TBL] [Abstract][Full Text] [Related]
33. Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors.
Kobzar G; Mardla V; Samel N
Platelets; 2011; 22(5):338-44. PubMed ID: 21557683
[TBL] [Abstract][Full Text] [Related]
34. Effects of antiplatelet therapy on platelet extracellular vesicle release and procoagulant activity in health and in cardiovascular disease.
Connor DE; Ly K; Aslam A; Boland J; Low J; Jarvis S; Muller DW; Joseph JE
Platelets; 2016 Dec; 27(8):805-811. PubMed ID: 27310292
[TBL] [Abstract][Full Text] [Related]
35. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment.
Stiff A; Trikha P; Wesolowski R; Kendra K; Hsu V; Uppati S; McMichael E; Duggan M; Campbell A; Keller K; Landi I; Zhong Y; Dubovsky J; Howard JH; Yu L; Harrington B; Old M; Reiff S; Mace T; Tridandapani S; Muthusamy N; Caligiuri MA; Byrd JC; Carson WE
Cancer Res; 2016 Apr; 76(8):2125-36. PubMed ID: 26880800
[TBL] [Abstract][Full Text] [Related]
36. Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib.
Lipsky AH; Farooqui MZ; Tian X; Martyr S; Cullinane AM; Nghiem K; Sun C; Valdez J; Niemann CU; Herman SE; Saba N; Soto S; Marti G; Uzel G; Holland SM; Lozier JN; Wiestner A
Haematologica; 2015 Dec; 100(12):1571-8. PubMed ID: 26430171
[TBL] [Abstract][Full Text] [Related]
37. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study.
Martin AC; Berndt C; Calmette L; Philip I; Decouture B; Gaussem P; Gouin-Thibault I; Samama CM; Bachelot-Loza C; Godier A
Eur J Anaesthesiol; 2016 May; 33(5):361-7. PubMed ID: 26351831
[TBL] [Abstract][Full Text] [Related]
38. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
Thorp BC; Badoux X
Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of collagen-induced platelet aggregation and adhesion by a pseudocyanide derivative of avicine isolated from Zanthoxylum integrifoliolum Merr.
Ko FN; Hsiao G; Chen IS; Wu SJ; Teng CM
Biochem Pharmacol; 1993 Oct; 46(7):1165-73. PubMed ID: 8216367
[TBL] [Abstract][Full Text] [Related]
40. Reference range determination for whole-blood platelet aggregation using the Multiplate analyzer.
Peerschke EI; Castellone DD; Stroobants AK; Francis J
Am J Clin Pathol; 2014 Nov; 142(5):647-56. PubMed ID: 25319980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
